A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Trial Profile

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2017 According to a Novartis media release, the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab). The label update includes 52-week data from this study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis. The updated label also includes use of Cosentyx to treat moderate-to-severe scalp psoriasis.
    • 24 May 2017 Results evaluating differential direct and indirect effects of secukinumab vs. ustekinumab on psoriasis symptoms and patient-reported work productivity and activity impairment (WPAI) at 52 weeks, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 24 May 2017 Results exploring differences in utilities and quality adjusted life years in German and UK presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top